usual treatment of glaucoma
PreclinicalSmall molecule
usual treatment of glaucoma is one of 31 small molecule programs targeting Open-Angle Glaucoma. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Open-Angle Glaucoma
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskApproved
Namenda
AbbVieApproved
Zolymbus
AbbVieApproved
Travatan
NovartisApproved
Xalatan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Mitosol
UUroGen Pharma Ltd.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Adrucil
EElorac, Inc.
Approved
Isopto Carpine
AAdvanz Pharma
Approved
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Open-Angle Glaucoma1 trial
Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma
Unknown status·—·N/A·NCT04499157·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for usual treatment of glaucoma. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details